J
J. Jiang-Wright
Publications - 3
Citations - 72
J. Jiang-Wright is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 72 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine
Karen Hager,Gonzalo Pérez Marc,Philipe Gobeil,Ricardo Sobhie Diaz,Gretchen M. Heizer,Conrado J. Llapur,Alexander I. Makarkov,Eduardo Vasconcellos,Stéphane Pillet,F Riera,Pooja Saxena,Priscila Geller Wolff,Kapil Bhutada,Garry Wallace,H.A. Aazami,Christine E. Jones,Fernando P. Polack,Luciana Ferrara,Judith Atkins,Iohann Boulay,Jiwanjeet Dhaliwall,Nathalie Charland,Manon Couture,J. Jiang-Wright,Nathalie Landry,Sophie Lapointe,Aurélien Lorin,Asif Mahmood,Lawrence H. Moulton,Emily Pahmer,Julie Parent,Annie Séguin,Luan Tran,Thomas Breuer,Maria Angeles Ceregido,Marguerite Koutsoukos,François Roman,Junya Namba,Marc-André D'Aoust,Sonia Trépanier,Yosuke Kimura,Brian J. Ward +41 more
TL;DR: The CoVLP+AS03 vaccine was effective in preventing Covid-19 caused by a spectrum of variants, with efficacy ranging from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.
Posted ContentDOI
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
Katrin Hager,Gonzalo Pérez Marc,Philipe Gobeil,Raúl² Silva Díaz,Gretchen M. Heizer,Conrado J. Llapur,Alexander I. Makarkov,E. Vasconcellos,Stéphane Pillet,F Riera,K. Bhutada,Patrice Wolff,Greg Wallace,H.A. Aazami,Caroline E. Jones,Fernando P. Polack,J. D. Atkins,Iohann Boulay,Jiwanjeet Dhaliwall,Nathalie Charland,Michele Couture,J. Jiang-Wright,Nathalie Landry,S. Lapointe,Aurélien Lorin,Asif Mahmood,Lawrence H. Moulton,Emmy Pahmer,Jason Parent,P. Saxena,Annie Séguin,Lillian Tran,Thomas Breuer,Maria Angeles Ceregido,Marguerite Koutsoukos,François Roman,J. Namba,Marc-André D'Aoust,Sonia Trépanier,Yoshiaki Kimura,The CoVLP Study Team,Brian J. Ward +41 more
TL;DR: The primary efficacy endpoint was prevention of symptomatic SARS-CoV-2 infection with onset at least 7 days after the second injection and was triggered by the identification of [≥]160 virologically-confirmed cases, and tolerability and safety of CoVLP+AS03 were also determined.
Journal ArticleDOI
Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities
Nathalie Charland,Philipe Gobeil,Stéphane Pillet,Iohann Boulay,Annie Séguin,Alexander I. Makarkov,Gretchen M. Heizer,Kapil Bhutada,Asif Mahmood,Sonia Trépanier,Karen Hager,J. Jiang-Wright,Judith Atkins,Pooja Saxena,Matthew P. Cheng,Donald C. Vinh,Philippe Boutet,François Roman,Robbert van der Most,Maria Angeles Ceregido,Marc Dionne,Guy Tellier,Jean-Sébastien Gauthier,Brandon Essink,Michael Libman,Jason Haffizulla,André Fréchette,Marc-André D'Aoust,Nathalie Landry,Brian J. Ward +29 more
TL;DR: The phase 2 portion of a Phase 2/3, randomized, placebo-controlled trial of a coronavirus virus-like particle (CoVLP) vaccine candidate, produced in plants that display the SARS-CoV-2 spike glycoprotein, adjuvanted with AS03 (NCT04636697), was reported in this article .